ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen To Buy Mustafa Nevzat For $700 Million

Biotechnology firm Amgen (AMGN) will buy a 95.6% stake in Mustafa Nevzat Pharmaceuticals for $700 million, in a move to expand its presence in Turkey and the surrounding region. The all-cash transaction has been approved by both the boards, the two companies said in a joint statement Wednesday. MN, which supplies pharmaceuticals to the hospital sector and is a major supplier of injectable medicines in Turkey, had revenue of approximately $200 million in 2011, the statement said. Amgen's focus on Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen, is a part of its international expansion strategy. Amgen established an affiliate in Turkey in 2010 and currently markets two products, with plans to develop its pipeline of clinical candidates for Turkey and other markets around the world. Order free Annual Report for Amgen, Inc. Visit http://djnewswires.ar.wilink.com/?link=AMGN or call 1-888-301-0513

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
03/28/201719:06:35Statement of Changes in Beneficial Ownership (4)
03/28/201719:04:45Statement of Changes in Beneficial Ownership (4)
03/28/201719:03:06Statement of Changes in Beneficial Ownership (4)
03/28/201719:00:45Statement of Changes in Beneficial Ownership (4)
03/28/201718:58:56Statement of Changes in Beneficial Ownership (4)
03/28/201718:57:10Statement of Changes in Beneficial Ownership (4)
03/28/201718:55:09Statement of Changes in Beneficial Ownership (4)
03/28/201718:52:54Statement of Changes in Beneficial Ownership (4)
03/28/201709:00:00Amgen Awards Three Golden Tickets for LabCentral Residency
03/23/201716:00:00European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) F...
03/19/201714:00:00Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate...
03/18/201708:00:00Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely...
03/17/201719:48:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke...
03/17/201714:05:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke...
03/17/201714:00:00Amgen's Money-Back Guarantee
03/17/201712:14:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke...
03/17/201709:29:00Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/17/201709:00:00Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases...
03/16/201716:00:00Amgen To Present At The Oppenheimer Global Health Care Conference
03/15/201717:18:54Securities Registration: Employee Benefit Plan (s-8)

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US